Form 10-Q INOVIO PHARMACEUTICALS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Inovio's (INO) DNA Technology Platform Further Validated with Latest Qtr. Results - Stifel
November 9, 2015 2:46 PM ESTStifel affirms its Buy rating and $19 price target on Inovio (Nasdaq: INO) following the company's Q3 report and update issued earlier Monday.
Analyst Thomas Shrader, PhD, CFA, noted that EPS of $0.07 was flat with consensus estimates and revenue was driven by... More
Inovio Pharma (INO) Swings to Q3 Profit
November 9, 2015 6:28 AM ESTInovio Pharma (NASDAQ: INO) reported Q3 EPS of $0.07, versus ($0.12) reported last year. Revenue for the quarter came in at $24.18 million, versus $1.84 million reported last year.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... More